The science and business of biotechnology.

Nature Biotechnology devotes pages specifically to in-depth analysis of issues concerning biotechnology intellectual property case law and policy, together with breaking news on patents. Also included in each issue are key emerging areas such as computational biology and materials science.

Aims and Scope: Nature Biotechnology is a monthly journal covering the science and business of biotechnology. It publishes applied research of relevance to the biological, biomedical, agricultural and environmental sciences as well as covering the commercial, political, ethical, legal and societal aspects of this research. (Biotechmedia.com)

Nature Biotechnology (Nat Biotechnol; ISSN 1087-0156) is an academic journal covering the science and business of biotechnology.

Nature Biotechnology is a continuation of Bio/technology (Biotechnology (NY); ISSN 0733-222X), which was founded in 1983 and renamed in 1996. It is published monthly by the Nature Publishing Group, a division of Macmillan Publishers Ltd. Like other Nature journals, there is no external Editorial Board; editorial decisions are made by an in-house team, although peer review by external expert referees forms a part of the review process.

Its 2005 impact factor was 22.7, making it the highest cited research journal in the category of biotechnology and applied microbiology, and one of the 20 most highly cited scientific journals. In comparison, the impact factors of general science journals Science and Nature for the same period were 30.927 and 29.273, respectively.

The current editor of Nature Biotechnology is Andrew Marshall. The founding editor of Bio/technology was Christopher Edwards. (Wikipedia.org)

Click Here, Get Nature Biotechnology, Free Subscription

• Qualify for Your Free Subscription!
• Geographic Eligibility: USA, Canada, Selected International
• Publisher: Nature Publishing Group

Read Nature Biotechnology, January 2009 Online

EDITORIAL
Begging bowls
The biotech sector needs government support, not blank checks.

The list of sectors seeking government help to see them through the credit crunch continues to lengthen. The banks, the construction industry and vehicle manufacturers—authors of their own downfall all—have each returned from their begging missions to governments with varying degrees of success, the very same governments whose interference in the free market they roundly rejected not so long ago. When the cargo of the bandwagon is cash or cheap credit, it is a pretty sure bet that many will jump on it. And now the biotech sector is right there too, collapsing market cap in hand.

There's no doubt that the inability to raise finance is rapidly becoming life threatening. For the firms in better financial health, the wintry funding environment is forcing the restructuring or shelving of key programs. ... 

NEWS FEATURE
Biotech's green gold?
Emily Waltz

Algae have long been touted as a rich and ubiquitous source of renewable fuel but thus far have failed to be economically competitive with other sources of energy. Could new advances change that? Emily Waltz investigates.

When the UK's Carbon Trust last year set out to fund algal biofuels research, organizers quickly met with a mélange of overzealous claims coming from the industry. Companies were projecting biofuel yields ten times what is theoretically possible and proposing techniques that are not now and may never be economical. A year later, after wading through the claims and gathering opinions from a network of more than 300 experts, the agency announced on October 23 the creation of the Algae Biofuel Challenge, a £16 ($24) million fund that will support the development and large-scale production of algal oil. ...

Comments (0)

Name

Email

Comment

smaller | bigger

Add Comment